Physician profile
Siamak Saadat
NPI 1992018642
$634,938.72
in general payments reported to CMS, 2019-2025
73 companies · $83K in 2025
The $83K reported for 2025 was more than what 98% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85K · 2020: $47K · 2021: $136K · 2022: $154K · 2023: $41K · 2024: $89K · 2025: $83K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $163K · Travel and Lodging: $18K · Food and Beverage: $16K · Consulting Fee: $15K · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $163,358.75 |
| Travel and Lodging | $18,497.45 |
| Food and Beverage | $16,201.87 |
| Consulting Fee | $15,015.00 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $253,027.97 | 2019-2025 | Opdivo, Reblozyl |
| Sobi, INC | $98,082.45 | 2022-2025 | |
| Dova Pharmaceuticals | $83,946.39 | 2019-2021 | |
| Lilly USA, LLC | $53,900.88 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Amgen INC. | $40,030.33 | 2019-2025 | Imdelltra (Amg757), Lumakras, Kyprolis |
| Pfizer INC. | $24,965.01 | 2019-2025 | |
| Taiho Oncology, INC. | $22,646.52 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $21,475.13 | 2019-2025 | |
| Global Blood Therapeutics, INC. | $6,583.37 | 2020-2022 | |
| Array Biopharma INC | $2,908.61 | 2020-2025 | Mektovi, Braftovi, Tukysa |
| Astrazeneca Pharmaceuticals Lp | $2,583.85 | 2019-2025 | Imfinzi, Enhertu, Calquence |
| Kite Pharma, INC. | $2,543.62 | 2020-2024 | Yescarta |
| Celgene Corporation | $2,467.44 | 2019-2025 | Pomalyst, Reblozyl, Opdualag |
| Merck Sharp & Dohme LLC | $2,289.76 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $2,077.46 | 2019-2025 | Erleada, Tecvayli, Darzalex |
Show all 73 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $1,960.50 | 2019-2025 | Provenge |
| Genentech USA, INC. | $1,408.61 | 2019-2025 | Venclexta, Polivy, Tecentriq |
| Genzyme Corporation | $861.33 | 2019-2025 | |
| Astellas Pharma US INC | $782.89 | 2019-2025 | Xtandi, Vyloy, Xospata |
| Gilead Sciences, INC. | $704.72 | 2019-2025 | Trodelvy |
| Incyte Corporation | $672.94 | 2019-2025 | Jakafi |
| Bayer Healthcare Pharmaceuticals INC. | $629.52 | 2019-2025 | |
| Eisai INC. | $618.11 | 2020-2025 | |
| Glaxosmithkline, LLC. | $554.46 | 2019-2024 | Zejula, Jemperli |
| Aveo Pharmaceuticals, INC. | $545.31 | 2021-2025 | Fotivda |
| Beigene USA, INC. | $447.03 | 2022-2025 | Brukinsa |
| Puma Biotechnology, INC. | $416.71 | 2019-2025 | |
| Exelixis INC. | $398.32 | 2019-2025 | Cabometyx |
| Regeneron Healthcare Solutions, INC. | $367.02 | 2022-2025 | Libtayo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $358.09 | 2019-2024 | Gilotrif |
| Seagen INC. | $337.17 | 2019-2025 | Padcev |
| Takeda Pharmaceuticals U.S.A., INC. | $326.90 | 2019-2024 | Fruzaqla, Iclusig |
| Alexion Pharmaceuticals, INC. | $296.13 | 2019-2025 | Ultomiris |
| Emd Serono, INC. | $293.30 | 2020-2025 | |
| Abbvie INC. | $280.04 | 2023-2025 | Venclexta |
| Pharmacyclics LLC, An Abbvie Company | $272.52 | 2019-2023 | Imbruvica |
| Karyopharm Therapeutics INC. | $265.60 | 2020-2025 | Xpovio |
| Sumitomo Pharma America, INC. | $191.22 | 2024-2025 | Orgovyx |
| Ipsen Biopharmaceuticals, INC | $182.47 | 2019-2024 | Somatuline Depot, Onivyde |
| Myovant Sciences INC. | $175.77 | 2021-2022 | |
| Springworks Therapeutics, INC. | $170.95 | 2024-2025 | Ogsiveo |
| Tesaro, INC. | $165.01 | 2019 | |
| Daiichi Sankyo INC. | $160.39 | 2020-2025 | Datroway, Enhertu, Vanflyta |
| Adc Therapeutics America, INC. | $146.02 | 2024-2025 | |
| Agios Pharmaceuticals, INC. | $136.86 | 2019-2025 | Pyrukynd |
| Janssen Pharmaceuticals, INC | $111.49 | 2020-2023 | Xarelto |
| Beone Medicines USA, INC. | $99.98 | 2025 | Brukinsa, Tevimbra |
| Pharmaessentia USA Corporation | $85.90 | 2022-2025 | Besremi |
| Terumo Bct, INC. | $68.02 | 2019-2022 | |
| Emmaus Medical, INC. | $65.67 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $58.37 | 2019 | |
| Iovance Biotherapeutics, INC. | $57.48 | 2025 | Amtagvi |
| Rigel Pharmaceuticals, INC. | $52.47 | 2022-2024 | Rezlidhia, Tavalisse |
| Legend Biotech USA INC. | $52.19 | 2024 | |
| Menarini Silicon Biosystems, INC. | $51.89 | 2024 | |
| Secura Bio, INC. | $49.33 | 2019-2025 | Copiktra |
| Mylan Institutional INC. | $47.94 | 2022 | |
| Tempus Ai, INC | $47.39 | 2024 | |
| Adaptive Biotechnologies Corporation | $45.75 | 2024 | Clonoseq |
| Servier Pharmaceuticals LLC | $43.55 | 2022-2024 | |
| Myriad Genetic Laboratories, INC. | $42.34 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $37.82 | 2019 | |
| Stemline Therapeutics INC. | $33.41 | 2019-2023 | Elzonris |
| Caris Mpi, INC. | $31.30 | 2025 | Mi Cancer Seek |
| Immunocore Limited | $28.70 | 2024 | Kimmtrak |
| Blueprint Medicines Corporation | $27.13 | 2023 | Ayvakit |
| Jazz Pharmaceuticals INC. | $26.63 | 2025 | |
| Foundation Medicine, INC. | $24.46 | 2019 | |
| Clovis Oncology, INC. | $24.39 | 2020 | |
| Acrotech Biopharma INC. | $21.23 | 2024 | Beleodaq |
| Tg Therapeutics, INC. | $16.85 | 2022 | |
| Immunomedics, INC. | $16.46 | 2020 | |
| Novo Nordisk INC | $15.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Siamak Saadat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.